BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol 2015; 7(28): 2792-2810 [PMID: 26668691 DOI: 10.4254/wjh.v7.i28.2792]
URL: https://www.wjgnet.com/1948-5182/full/v7/i28/2792.htm
Number Citing Articles
1
Radwa R. El-Tahan, Ahmed M. Ghoneim, Hosam Zaghloul. Dissection of two drug-targeted regions of Hepatitis C virus subtype 4a infecting Egyptian patientsVirus Genes 2020; 56(5): 564 doi: 10.1007/s11262-020-01776-y
2
Anissa Chouikha, Marwa Khedhiri, Hatem Triki, Walid Hammemi, Amel Sadraoui, Henda Touzi, Ahlem Ben Yahia, Amel Chtourou, Saba Gargouri, Lamia Feki Ben Rajah, Hela Hakim Karray, Henda Triki. Focus on hepatitis C virus genotype distribution in Tunisia prior to elimination: a 16-year retrospective studyArchives of Virology 2021; 166(2): 501 doi: 10.1007/s00705-020-04918-7
3
Dorota Zarębska-Michaluk, Jerzy Jaroszewicz, Anna Parfieniuk-Kowerda, Małgorzata Pawłowska, Ewa Janczewska, Hanna Berak, Justyna Janocha-Litwin, Jakub Klapaczyński, Krzysztof Tomasiewicz, Anna Piekarska, Rafał Krygier, Jolanta Citko, Olga Tronina, Krystyna Dobrowolska, Robert Flisiak. Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV CoinfectionJournal of Clinical Medicine 2022; 11(2): 389 doi: 10.3390/jcm11020389
4
Naiema K. Ali, Ragaa R. Mohamed, Bothina E. Saleh, Manal M. Alkady, Eman S. Farag. Occult hepatitis C virus infection among haemodialysis patientsArab Journal of Gastroenterology 2018; 19(3): 101 doi: 10.1016/j.ajg.2018.09.001
5
Dina Ragab, Dalia Samaha, Nesrine Mohamed, Mona Rafik, Walid Abdel Hady. Chronic hepatitis C virus infection impairs natural killer cells–dendritic cells cross‐talk: Anin vitroculture studyMicrobiology and Immunology 2021; 65(2): 76 doi: 10.1111/1348-0421.12858
6
Caroline E Boeke, Lindsey Hiebert, Imam Waked, Tengiz Tsertsvadze, Lali Sharvadze, Maia Butsashvili, Mamuka Zakalashvili, Win Naing, Neil Gupta, Fredrick Kateera, Craig McClure, John W Ward, Christian B Ramers. Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes From National Treatment Programs in Three Low- and Middle-Income CountriesClinical Infectious Diseases 2022; 74(3): 513 doi: 10.1093/cid/ciab461
7
Ali Jibran Mecci, Michelle Cheung. Encyclopedia of Life Sciences2017; : 1 doi: 10.1002/9780470015902.a0024786
8
G. Sanchez Antolin, M. Testillano, J.M. Pascasio, I. Narvaez Rodriguez, M. Prieto, A. Otero, J.I. Herrero, M. Londoño, I. Fernandez Vazquez, L. Castells, Xavier Xiol, Maria Luisa Gonzalez Dieguez, Mario Romero Cristobal, Jose Antonio Pons Miñano, Sonia Pascual Bartolome, Jose Luis Montero, Ana Arencibia, Sara Lorente, Esther Molina, Maria Dolores Espinosa, Valentin Cuervas-Mons, Emilio Fabrega Garcia. Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation CohortTransplantation Proceedings 2016; 48(9): 3013 doi: 10.1016/j.transproceed.2016.08.034
9
Youssef M. Mosaad, Shereen S. Metwally, Raghda E. Farag, Zakeria F. Lotfy, Hosam E. AbdelTwab. Association between Toll-Like Receptor 3 (TLR3) rs3775290, TLR7 rs179008, TLR9 rs352140 and Chronic HCVImmunological Investigations 2019; 48(3): 321 doi: 10.1080/08820139.2018.1527851
10
AbdullahS Alghamdi, Mohammed Alghamdi, FaisalM Sanai, Hamdan Alghamdi, Faisal Aba-Alkhail, Khalid Alswat, Mohammed Babatin, Adel Alqutub, Ibrahim Altraif, Faleh Alfaleh. SASLT guidelines: Update in treatment of Hepatitis C virus infectionSaudi Journal of Gastroenterology 2016; 22(8): 25 doi: 10.4103/1319-3767.188067
11
Sevin Kirdar, Neriman Aydin, Yasin Tiryaki, Bulent Ertugrul, Adil Coskun, Mehmet Bilgen. Dynamics of HCV epidemiology in Aydin province of Turkey and the associated factorsAPMIS 2018; 126(2): 109 doi: 10.1111/apm.12790
12
Awat Hasan, Zhian Ramzi, Mohammed Alshekhani. Seroprevalence and Genotypic Distribution Patterns of Hepatitis C Virus among Infected Patients from Sulaimaniyah Province: IraqJournal of Zankoy Sulaimani - Part A 2023; 25(1): 9 doi: 10.17656/jzs.10889
13
Andres Tabernilla, Ignacio Rego-Pérez, Marta Grandal, Berta Pernas, Sonia Pértega, Manuel Delgado, Ana Mariño, Hortensia Álvarez, Alvaro Mena, Iria Rodríguez-Osorio, Jose Domingo Pedreira, Francisco Javier Blanco, Eva Poveda. Brief Report: European Mitochondrial Haplogroups Impact on Liver Fibrosis Progression Among HCV and HIV/HCV-Coinfected Patients From Northwest SpainJAIDS Journal of Acquired Immune Deficiency Syndromes 2016; 73(2): 149 doi: 10.1097/QAI.0000000000001097
14
Gadissa Bedada Hundie, V. Stalin Raj, Daniel GebreMichael, Suzan D. Pas, Bart L. Haagmans, Jason Blackard. Genetic diversity of hepatitis C virus in EthiopiaPLOS ONE 2017; 12(6): e0179064 doi: 10.1371/journal.pone.0179064
15
Ahmed Nagaty, Ekram W. Abd El-Wahab, Tatsuo Kanda. Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in EgyptPLOS ONE 2017; 12(10): e0184654 doi: 10.1371/journal.pone.0184654
16
Mohamed Aboushady, Ahmed Alwassief, Mohamed Abdelrazik, Dina Ziada, Hossam Shahba, Amr Elmestikawy, Ashraf Elbahrawy. Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual TherapyJournal of Interferon & Cytokine Research 2019; 39(9): 539 doi: 10.1089/jir.2019.0041
17
G. Camus, B. Han, T. Asselah, D. Hsieh, H. Dvory‐Sobol, J. Lu, E. Svarovskaia, R. Martin, B. Parhy, M. D. Miller, D. M. Brainard, K. Kersey, A. Abergel, H. Mo. Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4Journal of Viral Hepatitis 2018; 25(2): 134 doi: 10.1111/jvh.12795
18
Masoud Keikha, Hossein Kamali, Kiarash Ghazvini, Mohsen Karbalaei. Antimicrobial peptides: natural or synthetic defense peptides against HBV and HCV infectionsVirusDisease 2022; 33(4): 445 doi: 10.1007/s13337-022-00790-y
19
Mainga Onchong’a Robert, Odari Okoth Eddy, Borus Kimutai Peter, Ole Kwallah Allan, Murithi Gikunda James, Osero Ong’ondo Bernard, Ruttoh Kiplangat Vincent, Mwandawiro Smiti Charles, Lihana Wekesa Raphael. Characterization of Hepatitis C virus circulating among injecting drug users (IDU) in Kilifi county, KenyaJournal of Human Virology & Retrovirology 2020; 8(2): 23 doi: 10.15406/jhvrv.2020.08.00217
20
Kholoud A. Saad, Mohammed A. Eldawy, Khaled M. Elokely. Studies of the symmetric binding mode of daclatasvir and analogs using a new homology model of HCV NS5A GT-4aJournal of Molecular Modeling 2023; 29(1) doi: 10.1007/s00894-022-05420-4
21
Allison M. Bell, Jamie L. Wagner, Katie E. Barber, Kayla R. Stover. Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis CInternational Journal of Hepatology 2016; 2016: 1 doi: 10.1155/2016/3852126
22
Mohamed A. Daw, Abdallah El-Bouzedi, Mohamed O. Ahmed, Aghnyia A. Dau, Mohamed M. Agnan. Epidemiology of hepatitis C virus and genotype distribution in immigrants crossing to Europe from North and sub-Saharan AfricaTravel Medicine and Infectious Disease 2016; 14(5): 517 doi: 10.1016/j.tmaid.2016.05.020
23
Dalia Omran, Mohamed Alboraie, Rania A Zayed, Mohamed-Naguib Wifi, Mervat Naguib, Mohamed Eltabbakh, Mohamed Abdellah, Ahmed Fouad Sherief, Sahar Maklad, Heba Hamdy Eldemellawy, Omar Khalid Saad, Doaa Mohamed Khamiss, Mohamed El Kassas. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitationsWorld Journal of Gastroenterology 2018; 24(38): 4330-4340 doi: 10.3748/wjg.v24.i38.4330
24
Dimitrios Paraskevis, Evangelia Georgia Kostaki, Anna Kramvis, Gkikas Magiorkinis. Hepatitis C: Epidemiology, Prevention and Elimination2021; : 55 doi: 10.1007/978-3-030-64649-3_3
25
Moataz M. Sayed, Ahmed I. El-Shafie, Ahmed Fathy Hilal, Hoda A. Abdelsattar. Can hepatitis C virus core antigen be used as a reliable marker of viral load for hepatitis C virus infection in genotype 4?Egyptian Liver Journal 2017; 7(1 and 2): 1 doi: 10.1097/01.ELX.0000523559.96944.09
26
Andréa Monteiro Tarragô, Grenda Leite Pereira, Flamir da Silva Victória, Adriana Malheiro Alle Marie, Marilú Barbieri Victória. Sofosbuvir and daclatasvir combination therapy for current hepatitis C virus genotype 4 achieves SVR: a case report of HCV genotype 4 from the AmazonRevista da Sociedade Brasileira de Medicina Tropical 2017; 50(6): 861 doi: 10.1590/0037-8682-0094-2017
27
Aly Atef Shoun, Rania Abozahra, Kholoud Baraka, Mai Mehrez, Sarah M. Abdelhamid. Identifying Different Mutation Sites Leading to Resistance to the Direct-Acting Antiviral (DAA) Sofosbuvir in Hepatitis C Virus Patients from EgyptMicroorganisms 2022; 10(4): 679 doi: 10.3390/microorganisms10040679
28
Etienne M. Sokal, Pilar Nannini. Chapter 6.1. Pediatric Chronic Hepatitis B and CJournal of Pediatric Gastroenterology and Nutrition 2018; 66(S1) doi: 10.1002/j.1536-4801.2018.tb00053.x
29
Patrick L. Iversen. Molecular Basis of Resilience2018; : 19 doi: 10.1007/978-3-319-98164-2_2
30
El‐Sayed Ibrahim, Mohamed Abdel‐Samiee, Mohamed I. Youssef, Helmy El‐Shazly, Abd‐ElAleem A.El‐Gendy, Ayman Ahmed Sakr, Doaa Elwazzan, Mervat Ragab Nassar, Amr Aly Elshormilisy, Ahmad Madkour, Mostafa Kamal, Yasmine M. Amrousy, Sally Waheed Elkhadry, Eman Abdelsameea. Variceal recurrence 4 years post endoscopic band ligation in hepatitis C patients who achieved sustained virological response with oral direct‐acting antiviral therapyJournal of Viral Hepatitis 2021; 28(2): 279 doi: 10.1111/jvh.13426
31
Neven A. Ebrahim, Hussein Abdelaziz Abdalla, Neimat Abd Elhakam Yassin, Aya Elsayed Maghrabia, Amira Ibrahim Morsy. Effect of Sofosbuvir on rats’ ovaries and the possible protective role of vitamin E: biochemical and immunohistochemical studyAnatomy & Cell Biology 2023; 56(4): 526 doi: 10.5115/acb.23.079
32
Radwa R. El-Tahan, Ahmed M. Ghoneim, Hosam Zaghloul. 5′ UTR and NS5B-based genotyping of hepatitis C virus in patients from Damietta governorate, EgyptJournal of Advanced Research 2018; 10: 39 doi: 10.1016/j.jare.2018.01.004
33
Ehab H. Mattar, Hussein A. Almehdar, Vladimir N. Uversky, Elrashdy M. Redwan. Virucidal activity of human α- and β-defensins against hepatitis C virus genotype 4Molecular BioSystems 2016; 12(9): 2785 doi: 10.1039/C6MB00283H
34
Anne Boerekamps, Thomas Vanwolleghem, Marc van der Valk, Guido E. van den Berk, Marjo van Kasteren, Dirk Posthouwer, Anthonius S.M. Dofferhoff, Bart van Hoek, Dewkoemar Ramsoekh, Jelle Koopsen, Janke Schinkel, Eric Florence, Joop E. Arends, Bart J. Rijnders. 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)Journal of Hepatology 2019; 70(3): 554 doi: 10.1016/j.jhep.2018.10.032
35
Nicola Coppola, Loredana Alessio, Lorenzo Onorato, Caterina Sagnelli, Margherita Macera, Evangelista Sagnelli, Mariantonietta Pisaturo. Epidemiology and management of hepatitis C virus infections in immigrant populationsInfectious Diseases of Poverty 2019; 8(1) doi: 10.1186/s40249-019-0528-6
36
Rania H. Khalifa, Rasha Mohamad Hosny Shahin, Reham Emad Eldin Aboukhalil, Mohamed A. Marie, Amr M. El-deeb, Nermine Magdi Riad. Digging more in the genetic risk prediction of hepatitis C virus epidemic in Egypt: Apoptosis genes polymorphisms in the susceptibility of hepatitis C virus and association with viral loadVirus Research 2017; 238: 35 doi: 10.1016/j.virusres.2017.05.025
37
Khalid S. Hassanien, El‐Sayed M. El‐Sayed, Raed S. Ismail, Zakarya M. Zakarya, Gouda K. Helal. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patientsJournal of Clinical Pharmacy and Therapeutics 2021; 46(4): 942 doi: 10.1111/jcpt.13417